Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20 % in Patients with Primary Immunodeficiency Diseases in North America

Patients with primary immunodeficiency disease (PIDD) typically require life-long intravenous (IV) or subcutaneous (SC) immunoglobulin (Ig) replacement therapy to prevent recurrent infections. The efficacy, safety, and pharmacokinetics of a highly concentrated (20 %) Ig preparation for SC administra...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Clin Immunol
Glavni autori: Suez, Daniel, Stein, Mark, Gupta, Sudhir, Hussain, Iftikhar, Melamed, Isaac, Paris, Kenneth, Darter, Amy, Bourgeois, Christelle, Fritsch, Sandor, Leibl, Heinz, McCoy, Barbara, Gelmont, David, Yel, Leman
Format: Artigo
Jezik:Inglês
Izdano: Springer US 2016
Teme:
Original Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5018260/
https://ncbi.nlm.nih.gov/pubmed/27582171
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10875-016-0327-9
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items